AstraZeneca PLC (AZNCF)
OTCMKTS
· Delayed Price · Currency is USD
155.75
+1.45 (0.94%)
Aug 14, 2025, 10:37 AM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
56.50B
Revenue Growth
+15.00%
P/S Ratio
4.26
Revenue / Employee
599.16K
Employees
94,300
Market Cap
240.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 206.83M |
| Elite Pharmaceuticals | 84.04M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| BioStem Technologies | 332.45M |
AstraZeneca News
- 1 day ago - UK Government, Eli Lilly Partner To Target Obesity Health Gaps - Benzinga
- 3 days ago - AstraZeneca: Great Portfolio, But Not A Great Price - Seeking Alpha
- 4 days ago - Melrose boss soars to top of the Footsie pay league - This is Money
- 7 days ago - Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (gMG) - Benzinga
- 8 days ago - SOPHiA GENETICS reaffirms $72M–$76M 2025 revenue guidance as AstraZeneca deal drives BioPharma outlook - Seeking Alpha
- 9 days ago - EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data - Benzinga
- 9 days ago - SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes - PRNewsWire
- 11 days ago - Top global stories this week: HSBC, AstraZeneca, Nissan among notable names - Seeking Alpha